Early Returns on Small Molecule Therapeutics for SARS-CoV-2 | Zendy

Mark Namchuk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Early Returns on Small Molecule Therapeutics for SARS-CoV-2

Author(s) -

Mark Namchuk

Publication year - 2021

Publication title -

acs infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.324

H-Index - 39

ISSN - 2373-8227

DOI - 10.1021/acsinfecdis.0c00874

Subject(s) - repurposing , pandemic , covid-19 , drug repositioning , small molecule , data science , computational biology , medicine , computer science , biology , virology , pharmacology , infectious disease (medical specialty) , disease , drug , ecology , genetics , pathology , outbreak

The COVID-19 pandemic has generated an unprecedented response within the scientific community. Extraordinary efforts have been undertaken to identify potential new therapeutics to treat SARS-CoV-2 infection spanning traditional medicinal chemistry, repurposing, and computational approaches. The breadth of the effort and rapid progression of many small molecules to clinical testing provide an opportunity to determine what chemical and testing approaches have been the most efficient in identifying potential treatments and how this may inform preparation for future pandemics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research